Concepedia

Author

Fabienne Portales

Institut de Recherche en Cancérologie de Montpellier

Also Known As

FABIENNE PORTALES, Fabienne Portales, Nicolas Tabchouri, Portales Fabienne, Portales, Fabienne, Portalès, Fabienne

67

Publications

1.8K

Citations

18

H-Index

16

Concepts

All Affiliations

Institut de Recherche en Cancérologie de MontpellierHôpital BeaujonSorbonne UniversitéAssistance Publique – Hôpitaux de ParisPitié-Salpêtrière Hospital
FP

About

Fabienne Portales is an author at Institut de Recherche en Cancérologie de Montpellier specializing in oncology, medicine, and radiation oncology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

8

8

446

2

Pharmacology

6

6

345

3

Health Sciences

3

3

76

4

Pathology

3

3

72

5

Gastroenterology

1

1

18

Fabienne Portales

×

20

Publications

1.5K

Citations

17

H-Index

YearCitations

Randomized Phase III Trial of Pegvorhyaluronidase Alfa With Nab-Paclitaxel Plus Gemcitabine for Patients With Hyaluronan-High Metastatic Pancreatic Adenocarcinoma

Eric Van Cutsem, Margaret A. Tempero, Darren Sigal,

Journal of Clinical Oncology

2020

404

Nab-paclitaxel plus gemcitabine in patients with locally advanced pancreatic cancer (LAPACT): a multicentre, open-label phase 2 study

Philip A. Philip, Jill Lacy, Fabienne Portales,

˜The œLancet. Gastroenterology & hepatology

2020

227

Resectable pancreatic adenocarcinoma neo-adjuvant FOLF(IRIN)OX-based chemotherapy - a multicenter, non-comparative, randomized, phase II trial (PANACHE01-PRODIGE48 study)

Lilian Schwarz, Déwi Vernerey, Jean‐Baptiste Bachet,

BMC Cancer

2018

114

Erythrocyte-encapsulated asparaginase (eryaspase) combined with chemotherapy in second-line treatment of advanced pancreatic cancer: An open-label, randomized Phase IIb trial

Pascal Hammel, Fabienne Portales, Laurent Mineur,

European Journal of Cancer

2019

106

The subgroups of the phase III RECOURSE trial of trifluridine/tipiracil (TAS-102) versus placebo with best supportive care in patients with metastatic colorectal cancer

Eric Van Cutsem, R. Mayer, Stéphanie Laurent,

European Journal of Cancer

2017

94

Dual targeting of HER1/EGFR and HER2 with cetuximab and trastuzumab in patients with metastatic pancreatic cancer after gemcitabine failure: results of the “THERAPY”phase 1-2 trial

Eric Assénat, D. Azria, Caroline Mollévi,

Oncotarget

2015

83

How Does Chemoradiotherapy Following Induction FOLFIRINOX Improve the Results in Resected Borderline or Locally Advanced Pancreatic Adenocarcinoma? An AGEO-FRENCH Multicentric Cohort

Daniel Pietrasz, Olivıer Turrini, V. Vendrely,

Annals of Surgical Oncology

2018

83

Cetuximab Plus FOLFIRINOX (ERBIRINOX) as First-Line Treatment for Unresectable Metastatic Colorectal Cancer: A Phase II Trial

Eric Assénat, Françoise Desseigne, Simon Thézenas,

The Oncologist

2011

80

Bevacizumab plus FOLFIRI or FOLFOX in chemotherapy-refractory patients with metastatic colorectal cancer: a retrospective study

Astrid Lièvre, Emmanuelle Samalin, Emmanuel Mitry,

BMC Cancer

2009

61

Safety, efficacy and patient-reported outcomes with trifluridine/tipiracil in pretreated metastatic colorectal cancer: results of the PRECONNECT study

Jean‐Baptiste Bachet, Lucjan Wyrwicz, Timothy Price,

ESMO Open

2020

44

Page 1